Alembic Pharmaceuticals USFDA nod adds 244th ANDA

Stock reaction and the key announcement

Alembic Pharmaceuticals rose 1.89% to Rs 786.05 after the company said it received final approval from the US Food and Drug Administration (USFDA) for Dapsone Gel, 5%. The approval is for the company’s abbreviated new drug application (ANDA) for the product. In the US generics business, an ANDA approval is a key regulatory step that allows a company to market a generic version of an already approved drug. In this case, Alembic said the approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Aczone Gel, 5%. Aczone Gel, 5% is marketed by Almirall, LLC. The product is indicated for the topical treatment of acne vulgaris.

What Alembic got approval for

The product approved is Dapsone Gel, 5%. Alembic said it is therapeutically equivalent to Aczone Gel, 5%, of Almirall, LLC. Therapeutic equivalence, as referenced in the company’s update, indicates the product is considered equivalent to the branded reference for its intended use. The indication mentioned is topical treatment of acne vulgaris. Acne vulgaris is a common skin condition, and topical treatments form a large part of routine dermatology prescriptions. Alembic’s approval adds a generic equivalent of Aczone Gel to its portfolio.

Market size for Dapsone Gel in the US

Alembic pointed to the US market opportunity for Dapsone Gel, 5% as an annual market estimated at US$ 18 million. The estimate was referenced as IQVIA MAT (moving annual total) for March 2026. The company also described the opportunity as niche, but one where it can leverage its existing dermatology distribution network. While the market size is not large by US generics standards, such products can still matter when a company is building depth in a specific therapy segment. For investors tracking USFDA approvals, the presence of a defined market size figure provides a clearer benchmark for the commercial potential, even if actual realised sales are not disclosed.

Why this approval matters for Alembic’s US generics strategy

The approval strengthens Alembic’s dermatology portfolio in the US market, as described in the company’s update. It also expands the list of products the company can market and sell in the American pharmaceutical sector. Alembic’s statement emphasised that the approval follows the submission and review process, and confirms bioequivalence to the branded reference. In practical terms, that clearance is what enables entry into the US market with a substitutable generic product. The company framed the approval as another step in expanding its product basket within dermatology.

Cumulative ANDA count: where it stands now

With this approval, Alembic Pharmaceuticals said it now has a cumulative total of 244 ANDA approvals from the USFDA. The company’s breakdown was 224 final approvals and 20 tentative approvals. The article text also references “as of June 29, 2026” for this cumulative count. For companies operating at scale in US generics, cumulative approvals are often tracked by investors as a proxy for product breadth and regulatory execution. Alembic’s latest update adds Dapsone Gel, 5% to that running tally.

June 2026: repeated regulatory wins referenced

The article text described this approval as the company’s fourth major regulatory win in June 2026. It positioned the month’s approvals as supportive of Alembic’s presence in the niche dermatological segment of the US generics market. Separate snippets in the provided text also mention USFDA approvals related to Tretinoin Cream USP, including a final approval for Tretinoin Cream USP, 0.05% (as the generic equivalent of Retin-A Cream) with an estimated market size of US$ 76 million for the 12 months ending March 2026, and references to Tretinoin Cream USP, 0.025%. However, the Dapsone Gel approval note is the specific regulatory event tied to the stock move and the updated cumulative ANDA count of 244.

Key data at a glance

Market impact: what investors are likely to track

The immediate market impact described in the text was the stock price move following the approval update. Beyond the day’s move, investors typically track whether such approvals translate into launches, pricing, and sustained volumes, but those details were not provided here. What is clear from the disclosure is that Alembic is adding another dermatology generic to its US portfolio, and it has identified the relevant market size for the product. The other number likely to remain in focus is the cumulative ANDA count, since it signals the pace at which the company is adding products that can be commercialised in the US. The approval also contributes to the company’s broader positioning in US generics, particularly within dermatology.

Conclusion

Alembic Pharmaceuticals said it received final USFDA approval for Dapsone Gel, 5%, a generic equivalent of Almirall’s Aczone Gel, for acne vulgaris. The company pegged the US market size for the product at about US$ 18 million annually and updated its cumulative USFDA ANDA approvals to 244, including 224 final and 20 tentative approvals. The stock rose 1.89% to Rs 786.05 after the announcement. Next, the market will watch for execution steps that typically follow such approvals, including any launch-related updates, when disclosed by the company.